{"id":"W3213981466","doi":"10.1182/blood-2021-148155","title":"Majic: A Phase 3 Prospective, Multicenter, Randomized, Open-Label Trial of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Venetoclax; Obinutuzumab; Ibrutinib; Medicine; Chronic lymphocytic leukemia; IGHV@; Internal medicine; Neutropenia; Tumor lysis syndrome; Oncology; Regimen; Leukemia; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001558622,0.001664204,0.001940783,0.0004710217,0.0004822782,0.001487454,0.0009825451,0.001282476,0.005322719],"category_scores_gemma":[0.0009679658,0.0005543666,0.001298159,0.0004550482,0.001177428,0.000968541,0.0003656407,0.003601243,0.001110489],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001002555,"about_ca_system_score_gemma":0.001398187,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009115748,"about_ca_topic_score_gemma":0.00236332,"domain_scores_codex":[0.9996124,0.0001983561,0.00001565997,0.00006876953,0.00002685006,0.00007804419],"domain_scores_gemma":[0.9993684,0.0001052349,0.0001298609,0.00004290038,0.00003331454,0.0003203521],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.953222,0.01328218,0.00107112,0.0006900757,0.0007777455,0.00007781105,0.0000774553,0.0006815514,0.006191264,0.000305035,0.001692424,0.02193128],"study_design_scores_gemma":[0.9060865,0.08966137,0.001865779,0.00003170813,0.0002642635,0.00006414039,0.00002902584,0.0004601205,0.0004041027,0.0002051207,0.0009138009,0.00001399978],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9854608,0.005365867,0.0005475708,0.0007180672,0.0005385402,0.003358351,0.001176965,0.0001797093,0.002654137],"genre_scores_gemma":[0.9860851,0.002557052,0.00137211,0.001355389,0.0004497743,0.003625796,0.001691656,0.00002748017,0.002835781],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005322719,"threshold_uncertainty_score":0.01780629,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06305773727376265,"score_gpt":0.3625124696844897,"score_spread":0.2994547324107271,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}